Optimi Health is trading at $3.55, up +5.65%, with biotech-sector strength the clearest available context.
- The supplied sector update says XBI is up 2.10%, amid M&A activity and positive clinical-trial news.
- On October 20, Optimi announced it completed an MDMA production batch for a proposed Canadian Phase 3 PTSD trial, a MAPS trial in Israel, and planned Australian commercial supply; no source confirms this caused the October 21 move.
- No current-session volume figures were available.